- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06164756
Long Term Follow Up KET-PD
December 1, 2023 updated by: Sophie Holmes, Yale University
Long-Term Follow-Up for Subjects Enrolled in the Ketamine for the Treatment of Depression in Parkinson's Disease (KET-PD) Trial
The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
This is a roll-out study from the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394).
We will adopt an implementation science approach to have participants across ketamine and placebo groups in one of two arms: a) follow-up with treatment as usual (TAU) (at 3 and 6 months post-infusions); b) follow-up with 3 months of Cognitive Behavior Therapy (CBT) post-infusions, delivered remotely once per week, with follow-up assessments at 3 and 6 month timepoints.
CBT is expected to have a superior sustained antidepressant response to the TAU follow-up group in both ketamine and placebo arms.
We hypothesize that ketamine + CBT will show the most superior antidepressant response at follow-up.
Study Type
Observational
Enrollment (Estimated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale New Haven Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
A total of n=56 participants with PD and comorbid depression, age 40-80, are being recruited under the parent clinical trial.
As of July 2023, 20 participants have been enrolled.
We aim to follow-up our remaining participants longitudinally and, within this, to have 20 prospective participants receive CBT, such that we will have 20 participants in each follow-up arm (CBT vs. TAU), and ultimately 10 in each group (ketamine + CBT, ketamine + TAU, placebo + CBT, placebo + TAU).
Description
Eligibility is determined in the ongoing parent clinical trial (KET-PD trial; NCT04944017, HIC 2000030394).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Experimental: Ketamine Infusion
Participants who received 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total), administered over 40 minutes while on continuous cardiac monitoring and oximetry in the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394)
|
Participants will receive 10 weeks of CBT
Participants will receive standard of care treatment
|
Placebo Comparator: Saline Infusion
Participants who received 6 infusions of placebo (saline IV), administered over 40 minutes while on continuous cardiac monitoring and oximetry in the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394)
|
Participants will receive 10 weeks of CBT
Participants will receive standard of care treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long-Term Change in Depression Severity
Time Frame: 3 Months and 6 Months
|
Change in MADRS score following course of ketamine vs. placebo treatment at 3 and 6 month timepoints; and change in MADRS across treatment (ketamine/placebo) and follow-up (CBT/TAU) arms at 3 and 6 month timepoints.
The scale used to measure depression severity is called The Montgomery-Åsberg Depression Rating Scale (MADRS).
The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders.
The overall score ranges from 0 to 60, higher MADRS score indicates more severe depression.
|
3 Months and 6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Apathy
Time Frame: 3 Months and 6 Months
|
Changes in apathy determined by the Starkstein Apathy Scale (SAS) scale
|
3 Months and 6 Months
|
Change in Anxiety
Time Frame: 3 Months and 6 Months
|
Changes in anxiety determined by the State-Trait Anxiety Inventory (STAI) scale
|
3 Months and 6 Months
|
Change in Parkinson's Symptom Severity
Time Frame: 3 Months and 6 Months
|
Changes in Parkinson's symptom severity determined by the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale
|
3 Months and 6 Months
|
Change in Dyskinesia
Time Frame: 3 Months and 6 Months
|
Changes in dyskinesia determined by the Unified Dyskinesia Rating Scale (UDysRS) scale
|
3 Months and 6 Months
|
Change in Pain
Time Frame: 3 Months and 6 Months
|
Changes in pain determined by the King's PD Pain Scale
|
3 Months and 6 Months
|
Change in Fatigue
Time Frame: 3 Months and 6 Months
|
Changes in fatigue determined by the Parkinson's Fatigue Scale (PFS)
|
3 Months and 6 Months
|
Change in Anhedonia
Time Frame: 3 Months and 6 Months
|
Changes in anhedonia determined by the Snaith-Hamilton Pleasure Scale (SHAPS)
|
3 Months and 6 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sophie E. Holmes, PhD, Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 18, 2023
Primary Completion (Estimated)
February 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
December 1, 2023
First Submitted That Met QC Criteria
December 1, 2023
First Posted (Estimated)
December 11, 2023
Study Record Updates
Last Update Posted (Estimated)
December 11, 2023
Last Update Submitted That Met QC Criteria
December 1, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000036071
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Cognitive Behavior Therapy (CBT)
-
Baylor College of MedicineSouth Central VA Mental Illness Research, Education & Clinical CenterCompletedDepression | AnxietyUnited States
-
Karolinska InstitutetUppsala UniversityCompleted
-
Ohio State University Comprehensive Cancer CenterCompletedMajor Depressive DisorderUnited States
-
Mayo ClinicRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingBone SarcomaUnited States
-
University of UtahCompletedSedentary Lifestyle | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7United States
-
Baylor College of MedicineRetirement Research Foundation; Archstone FoundationCompletedGeneralized Anxiety Disorder | Anxiety Disorder NOSUnited States
-
Karolinska InstitutetRegion StockholmCompletedPanic DisorderSweden
-
Karolinska InstitutetRegion Stockholm; Aleris Helse; Allmänna arvsfonden; Königska-Söderströmska sjukhemmetCompletedIrritable Bowel SyndromeSweden
-
Vanderbilt UniversityNational Institute of Mental Health (NIMH)Completed